The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic
The coronavirus disease 2019 (COVID-19) outbreak emerged in December 2019 in China and rapidly spread worldwide. Inflammatory bowel disease (IBD) patients are likely to be more susceptible to viral infections, and this is significantly influenced by the type of therapy they receive. Thus, issues spe...
Main Authors: | Klaudia Farkas, Daniella Pigniczki, Mariann Rutka, Kata Judit Szántó, Tamás Resál, Renáta Bor, Anna Fábián, Zoltán Szepes, György Lázár, Tamás Molnár |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-04-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756284820988198 |
Similar Items
-
Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
by: Péter Bacsur, et al.
Published: (2023-06-01) -
Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
by: Tamás Resál, et al.
Published: (2023-06-01) -
Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center.
by: Kata Szántó, et al.
Published: (2018-01-01) -
Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.
by: Renáta Bor, et al.
Published: (2017-01-01) -
Ustekinumab is associated with superior treatment persistence but not with higher remission rates vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
by: Péter Bacsur, et al.
Published: (2022-12-01)